首页> 外文期刊>Pediatric Hematology Oncology Journal >Twenty-seven year follow-up of Fanconi Anemia from REFAIN (Registry for Fanconi Anemia in India)-Finite disappointment and infinite hope
【24h】

Twenty-seven year follow-up of Fanconi Anemia from REFAIN (Registry for Fanconi Anemia in India)-Finite disappointment and infinite hope

机译:REFAIN(印度Fanconi贫血注册机构)对Fanconi贫血进行了27年的随访-有限的失望和无限的希望

获取原文
           

摘要

Nineteen children were included in study with a median age atdiagnosis of eight years (1 year to 18 years). The median total leukocytecount at presentation was 10,200 (4500 to 500,000). B-myeloid in fifteen,T-myeloid in two and B/T lymphoid in two children were the immuno-phenotype documented. Eleven patients received AML induction therapyand 8 patients received ALL induction therapy. Eight out of thirteen chil-dren who underwent allogeneic hematopoietic stem cell transplantationfrom the best available donor and two of the five patients who did notundergo HSCT are alive. The overall survival in our cohort was 42.1%. Themost common cause of mortality was relapse (66%) followed by regimenrelated toxicity (33%).
机译:纳入研究的19名儿童的平均年龄诊断为8岁(1岁至18岁)。呈现时的白细胞总数中位数为10,200(4500至500,000)。免疫表型中有15例中的B-髓样,2例中的T-髓样和2例儿童的B / T淋巴样。 11例接受AML诱导治疗,8例接受ALL诱导治疗。从可获得的最佳供体中接受异体造血干细胞移植的13名儿童中,有8名儿童未接受HSCT的5名患者中有2名还活着。我们队列的总生存率为42.1%。死亡的最常见原因是复发(66%),其次是与方案相关的毒性(33%)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号